<DOC>
	<DOCNO>NCT01469143</DOCNO>
	<brief_summary>This trial conduct Europe . The purpose trial compare pharmacokinetic property ( exposure trial drug body ) different formulation NN1218 .</brief_summary>
	<brief_title>A Trial Investigating Pharmacokinetic Properties Formulations NN1218 Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 1 diabetes mellitus 12 month Treated multiple daily insulin injection continuous subcutaneous insulin infusion ( CSII ) 12 month Body mass index ( BMI ) 18.028.0 kg/m^2 ( inclusive ) Subjects donate blood plasma past month 500 mL within 3 month prior trial start Smoker ( define subject smoke 5 cigarette equivalent per day ) Not able willing refrain smoking use nicotine gum transdermal nicotine patch inpatient period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>